Specific immunotherapy suppresses IL-8-levels in nasal secretions: A possible explanation for the inhibition of eosinophil migration;Suppression der IL-8-Sekretion in das Nasensekret durch die spezifische Immuntherapie: Mogliche Ursache der gehemmten Migration eosinophiler Granulozyten?

Allergologie

Volumn 20, Issue 4, 1997, Pages 184-191

  Hauser, U ^a,b   Wagenmann, M ^a   Rudack, C ^a   Bachert, C ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b NONE   (Germany)

Author keywords

allergic rhinitis; cytokines; IL 6; IL 8; nasal secretions; specific allergen immunotherapy

Indexed keywords

ALLERGEN; ALLERGOVIT; INTERLEUKIN 6; INTERLEUKIN 8; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; NOSE MUCOSA; NOSE SECRETION;

EID: 0030950070     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bachert C , U. Ganzer: Allergische Rhinitis: Zellen und Mediatoren in der Sofort- und Spätphase, Teil 1; Mastzellen und basophile Granulozyten. Otorhinolarygol. Nova 1, 46-52 (1991).
2. Bachert C., U. Ganzer: Allergische Rhinitis: Zellen und Mediatoren in der Sofort- und Spätphase, Teil 2: Eosinophile Granulozyten und T-Lymphozyten, Makrophagen und Monozyten, neutrophile Granulozyten und epitheliale Zellen. Otorhinolarygol. Nova 1, 69-74 (1991).
3. Bachert C., G. Schindlbeck, U. Hauser: Cellular infiltration in allergic late phase reaction of the nose: immunohistochemical studies. Am. J. Rhinol. 5, 227-233 (1991).
4. Bachert C., U. Hauser, B. Prem, C. Rudack, U. Ganzer: Proinflammatory cytokines in allergic rhinitis. Eur. Arch. Otorhinolaryngology 252, S44-S49 (1995).
5. Collins P.D., V.B. Weg, L.H. Faccioli, M.L. Watson, K. Moqbel, T.J. Williams: Eosinophil accumulation induced by human interleukin 8 in the guinea-pig in vivo. Immunology 79, 312-318 (1993).
6. Durham S.R., V. Varney, A.J. Gaga, M. Jacobson, A.B. Kay: Immunotherapy and allergic inflammation. Clin. Exp. Allergy 21, 206-210 (1991).
7. Durham S.R., S. Ying, V.A. Varney, M.R. Jacobson, R.M. Sudderick, I.S. Mackay, A.B. Kay, Q.A. Hamid: Cytocine messenger RNA expression for IL-3, IL-4, IL-5 and granulocyte/macrophage colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J. Immunol. 148, 2390-2394 (1992).
8. Furin M.J., P.S. Norman, P.S. Creticos, D. Proud, A. Kagey-Sabotka, L.M. Lichtenstein, R.M. Naclerio: Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J. Allergy Clin. Immunol. 88, 27-32 (1991).
9. Gleich G.J.: The late phase of the immunoglobuin E-mediated reaction. A link between anaphylaxis and common allergic disease? J. Allergy Clin. Immunol. 70, 160-169 (1982).
10. Gonsior E , C. Bachert, D. Berdel: Richtlinien für die Durchführung von nasalen Provokationstests mit Allergenen bei Erkrankungen der oberen Luftwege. Allergologie 13, 53-55 (1990).
11. Greenstein J.L., J.P. Morgenstern, J. La Raia, C.M. Councell, D.H. Goodwin, A. Lussier, P.S. Creticos, P.S. Norman, R.D. Garman: Ragweed immunotherapy decreases T-cell reactivity to recombinant Amb a I. J. Allergy Clin. Immunol. 89, 322 (1992).
12. Hashimoto S., E. Amemiya, Y. Tomita, T. Kobatashi, K. Arai, M. Yamaguchi, T. Horie: Elevation of soluble IL-2 receptor and IL-4 and nonelevation of IFN-gamma in sera from patients with allergic asthma. Ann. Allergy 71, 455-458 (1993).
13. Hauser U., C. Bachert, E. Frank: Hemmung des Einstroms von Emzündungszellen in die Nasenschleimhaut durch die allergenspezifische Immuntherapie. Allergo J. 4, 164-171 (1995).
14. Hauser U., C. Bachert, B. Prem, U. Ganzer: Zellwanderung und Symptomatik in der allergischen Spätphase-Reaktion der Nase. Allergologie 15, 192-172 (1992).
15. Kotowicz K., R.E. Callard: Human immunoglobulin class and IgG subclass regulation: dual action of interleukin-4. Eur. J. Immunol. 23, 2250-2256 (1993).
16. Kleine-Tebbe J., G. Kunkel: Wirkungsweise der allergenspezifischen Immuntherapie bei inhalativen Allergien vom Soforttyp. Allergo J. 3, 260-265 (1994).
17. Malling H.J., B. Wecke: Position Paper: Immunotherapy. Allergy 48 (Suppl 14), 9-35 (1993).
18. Norman P.S.: Immunotherapy for nasal allergy. J Allergy Clin. Immunol. 81, 992-996 (1988).
19. Rak S., A. Bjorenson, L. Hukanson, S. Sörenson, P. Venge: The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J. Allergy Clin. Immunol. 88, 878-888 (1991).
20. Rak S., L. Hakanson, P. Venge: Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J. Allergy Clin. Immunol. 86, 706-713 (1990).
21. 2-type cytokine mRNA expression and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J. Allergy Clin. Immunol 92, 313-324 (1993).
22. Röseler S., C Bachert, M. Wagenmann, G. Holtappels: Elevated levels of cytokines in viral rhinitis. Eur. Arch. Otorhinolaryngology 252, S61-S63 (1995).
23. Sehmi R., O. Cromwell, A.J. Wardlaw, R. Moqbel, A.B. Kay: Interleukin 8 is a chemo-attractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects. Clin. Exp. Allergy 23, 1027-1036 (1993).
24. Sennekamp J., W. Kersten, E. Fuchs, B. Hornung: Empfehlungen zur Hyposensibilisierung mit Allergenextrakten Allergologie 13, 185-188 (1990).
25. Shute J.: Interleukin 8 is a potent eosinophil chemo-attractant. Clin. Exp. Allergy 24, 203-206 (1994).
26. Varney V.A., Q. Hamid, M. Gaga, S. Ying, M. Jacabsen, A.J. Frew, A.B. Kay, S.R. Durham: Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous response. J. Clin. Invest. 92, 644-651 (1993).
27. Varney A., M. Gaga, A.J. Frew, V.R. Aber, A.B. Kay, S.R. Durham: Usefulness of immunotherapy in patients with severe summer hayfever uncontrolled by antiallergic drugs BMJ 302, 265-269 (1991).
28. World Health Organization: Current status of allergen immunotherapy (Hyposensitization). memorandum from a WHO/IUIS-Meeting. Bull. World Health Organ. 67, 263-272 (1989)